reviewed april 2026|next review october 2026|88 physicians psi has verified|29559 published studies
Catestatin
Catestatin is a 21-amino-acid naturally occurring (the body's own) peptide derived from chromogranin A that functions as the body's natural brake on catecholamine (adrenaline) release, with low plasma levels serving as a biomarker for hypertension risk and additional antimicrobial and cardioprotective properties.
Evidence landscape: 29559 published studies
Published studies indexed under this compound. The broader chromogranin A literature encompasses thousands of papers, though catestatin-specific studies are a subset.
- 11 Human
- 175 Animal
- 14 Reviews
- 29359 Other research
Not FDA-approved. No catestatin-based therapeutic is in clinical development. Research interest centers on its role as a cardiovascular biomarker and potential therapeutic target.
Not commercially available as a therapeutic. Naturally occurring (the body's own) peptide released from adrenal chromaffin cells and immune cells. Available as a research compound from specialty suppliers.
A biologically active fragment of chromogranin A (CgA), one of the most abundant proteins in neuroendocrine secretory granules. Genome-wide association studies link chromogranin A genetic variants to hypertension risk, providing human genetic evidence for catestatin's biological relevance.
PSI Assessment
People with naturally lower catestatin levels tend to develop higher blood pressure. That observation, replicated across multiple human cohorts, positioned catestatin as both a cardiovascular biomarker and a window into how the body normally keeps adrenaline in check. Catestatin is released from the same cells that release adrenaline and acts as a feedback brake on further release. When that brake is weak (low catestatin), the sympathetic nervous system runs hotter. The biology spans cardiovascular regulation, innate immunity, and metabolic function.
The body's natural brake on adrenaline release. Low levels predict hypertension in human studies. Also has direct antimicrobial and cardioprotective activity.
The mechanism is nicotinic acetylcholine receptor antagonism on chromaffin cells. When nerve signals stimulate the adrenal medulla to release catecholamines (adrenaline, noradrenaline), catestatin is co-released and feeds back to inhibit further release. This creates a negative feedback loop that prevents excessive sympathetic activation. Beyond this primary mechanism, catestatin also kills bacteria directly, reduces cardiac fibrosis in animal models (animal research), and shifts macrophage polarization toward anti-inflammatory phenotypes.
What the evidence supports
Catestatin inhibits catecholamine release from chromaffin cells through nicotinic receptor antagonism, a mechanism validated across multiple laboratories. Low plasma catestatin levels correlate with hypertension risk in human observational studies, positioning it as a cardiovascular biomarker. Direct antimicrobial activity against gram-positive and gram-negative bacteria is documented.
What is not yet established
Whether exogenous catestatin administration produces cardiovascular benefits in humans. Whether the human biomarker association reflects a causal relationship amenable to therapeutic intervention. Optimal delivery and dosing for potential therapeutic use.
Research Evidence
The findings below cover the biomarker evidence from human studies, the pharmacological mechanism, and the animal studies therapeutic potential.
Evidence by condition
Evidence dimensions across catestatin research areas. Hypertension biomarker data has the strongest human evidence. Cardiovascular and antimicrobial effects are characterized in animal models (animal research).
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Hypertension | ||||
| Cardiovascular Protection | ||||
| Catecholamine Regulation | ||||
| Antimicrobial Defense |
Human studies demonstrate that patients with essential hypertension have significantly lower plasma catestatin levels than normotensive controls. Genome-wide association studies link chromogranin A genetic variants to hypertension risk.
The biomarker association is consistent across multiple cohorts. Whether low catestatin is a cause or consequence of hypertension is not definitively established. Genetic evidence supports a causal contribution.
Catestatin inhibits catecholamine release from chromaffin cells by acting as a noncompetitive nicotinic cholinergic antagonist. This creates a negative feedback loop that limits excessive sympathetic nervous system activation.
The mechanism has been characterized at the molecular level. Chromogranin A, the parent protein from which catestatin is cleaved, is one of the most abundant proteins in neuroendocrine secretory granules.
Catestatin has direct antimicrobial activity against gram-positive and gram-negative bacteria. It also reduces cardiac ischemia-reperfusion injury and modulates macrophage polarization toward anti-inflammatory phenotypes in animal models (animal research).
The multifunctional nature of catestatin reflects the broader pattern of naturally occurring peptides having overlapping cardiovascular and immune functions. Therapeutic development for any of these applications remains in animal models.
11 Human|175 Animal|14 Reviews
View all 29559 indexed studiesHow Catestatin Works
Catestatin is released from adrenal glands alongside adrenaline and acts as a natural brake on further adrenaline release. Think of it as the body's built-in system for preventing the fight-or-flight response from running unchecked. When catestatin levels are low, the brake is weaker and blood pressure tends to be higher.
Catestatin is released from adrenal glands and immune cells. It acts as a brake on adrenaline release, keeping blood pressure in check. It also fights infections directly by killing bacteria. People with naturally lower catestatin levels tend to have higher blood pressure.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Catestatin (chromogranin A352-372) is a 21-amino-acid peptide generated by proteolytic processing of chromogranin A in neuroendocrine secretory granules. It inhibits nicotinic acetylcholine receptor-mediated catecholamine release from chromaffin cells and sympathetic neurons through noncompetitive antagonism. It also activates histamine H1 receptors for vasodilation, has direct antimicrobial activity via membrane disruption, reduces cardiac fibrosis through anti-inflammatory macrophage polarization (M1 to M2 shift), and modulates metabolic parameters including insulin sensitivity in animal models.
What is Catestatin being studied for?
Researchers are studying Catestatin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Catestatin overall. This means a compound can have human studies for one condition but only animal data for another.
Hypertension
·Human TrialsLow plasma catestatin levels correlate with hypertension in multiple human cohorts. Genome-wide association studies link chromogranin A variants to blood pressure regulation.
Limitations: Human evidence is observational (biomarker association), not interventional. Whether catestatin supplementation would lower blood pressure is untested. The causal direction of the association is supported by genetic evidence but not proven by clinical trials.
Cardiovascular Protection
·Animal StudiesCatestatin reduces cardiac ischemia-reperfusion injury and promotes angiogenesis in animal models (animal research). It inhibits cardiac fibrosis through macrophage polarization.
Limitations: Cardioprotective effects demonstrated only in animal models. No human interventional cardiovascular data.
Catecholamine Regulation
·Animal StudiesCatestatin inhibits catecholamine release through nicotinic receptor antagonism. This is the primary characterized mechanism with implications for sympathetic nervous system regulation.
Limitations: The feedback mechanism is well characterized in cell and animal systems. Whether exogenous catestatin can therapeutically modulate catecholamine release in humans is untested.
Antimicrobial Defense
·PreclinicalCatestatin has direct bactericidal activity against gram-positive and gram-negative bacteria through membrane disruption.
Limitations: Antimicrobial activity demonstrated in laboratory assays (in vitro research). Clinical relevance of catestatin's antimicrobial function is not established.
Safety and Regulatory Status
FDA Status: Not FDA-approved. No catestatin-based therapeutic exists. Research interest is in biomarker applications and understanding naturally occurring cardiovascular regulation.
Availability: Not commercially available as a therapeutic. Available as a research compound from specialty peptide suppliers.
Class context: Naturally occurring (the body's own) peptide with no safety concerns identified from normal physiology. No human therapeutic administration studies have been conducted.
Catestatin is naturally occurring (the body's own) with no safety concerns from normal physiology. No human therapeutic studies have been conducted, so a formal safety profile does not exist. The primary research interest is in understanding its role as a cardiovascular biomarker.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Catestatin discussion.
Comparison and Related Research
Catestatin is compared with other naturally occurring (the body's own) cardiovascular regulatory peptides.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Identified catestatin as a biologically active fragment of chromogranin A that inhibits catecholamine release from adrenal chromaffin cells. By acting as a noncompetitive nicotinic receptor antagonist, catestatin functions as a natural brake on the fight-or-flight adrenaline response. This foundational work established catestatin as an endogenous regulator of sympathetic nervous system activity.Mahata SK et al., 2005 in J Biol Chem. View on PubMed
- 2.Measured circulating catestatin levels in patients with essential hypertension and normotensive controls. Hypertensive patients had significantly lower plasma catestatin, suggesting that reduced catestatin-mediated inhibition of catecholamine release may contribute to elevated blood pressure. This positioned catestatin as a biomarker and potential mechanistic link in human hypertension.O'Connor DT et al., 2008 in Hypertension. View on PubMed
- 3.Comprehensive review covering the expanding biological roles of catestatin beyond catecholamine regulation. The paper described evidence for catestatin's antimicrobial activity, anti-inflammatory properties, metabolic effects including insulin sensitivity modulation, and cardiovascular protective functions across multiple research models.Zhu D et al., 2017 in Acta Physiol (Oxf). View on PubMed
- 4.Meta-analysis pooling data from multiple human studies that measured catestatin levels in cardiovascular disease. The analysis confirmed that patients with hypertension, heart failure, and coronary artery disease had altered catestatin concentrations compared to healthy individuals, supporting its utility as a cardiovascular biomarker.Peng F et al., 2018 in Clin Chim Acta. View on PubMed
- 5.Updated review covering the therapeutic potential of catestatin across cardiovascular, metabolic, immune, and gastrointestinal domains. The paper described recent evidence for catestatin's role in modulating gut microbiome composition, reducing obesity-related inflammation, and protecting against cardiac ischemia-reperfusion injury.Bourebaba Y et al., 2022 in Biomolecules. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.